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A B S T R A C T
Reactive Oxygen Species (ROS) are key mediators of ischemia-reperfusion injury but also required for the
induction of the stress response that limits tissue injury and underlies the protection provided by ischemic-
preconditioning protocols. Liver steatosis is an important risk factor for liver transplant failure. Liver steatosis is
associated with mitochondrial dysfunction and excessive mitochondrial ROS production. Studies aiming at
decreasing the sensibility of the steatotic liver to ischemia-reperfusion injury using pre-conditioning protocols,
have shown that the steatotic liver has a reduced capacity to respond to these protocols. Recent studies indicate
that these eﬀects are related to a reduced capacity of the steatotic liver to respond to elevated ROS levels
following reperfusion by inducing a compensatory response. This failure to respond to ROS is associated with
reduced levels of antioxidants, mitochondrial damage, hepatocyte cell death, activation of the immune system
and induction of pro-ﬁbrotic mediators.
1. Liver transplants
The prevalence of the steatotic liver is rapidly increasing worldwide
reaching almost 30% of the total population in some countries [1,2],
with incidences rapidly rising in the pediatric population [3]. Hepatic
steatosis is largely considered the hepatic manifestation of the meta-
bolic syndrome [4], although, in fact, recent studies have shown that it
actually precedes the development of metabolic syndrome [5] and its
prevalence is expected to rise along with the number of overweight and
obese people [6]. Traditionally considered a benign condition, a
plethora of studies have more than clearly demonstrated that the
steatotic liver is more sensitive than the lean liver to a vast array of
pathological insults, and the most prevalent and signiﬁcant risk factor
for the development of NAFLD [7–9].
The particular sensitivity of the steatotic liver has been dramatically
attested in the transplant ﬁeld [10]. Liver and kidney are the most
commonly transplanted organs. Liver transplantation is the only
treatment option for end-stage liver disease, acute hepatic failure,
hepatocellular carcinoma (HCC), hilar cholangiocarcinoma and several
other disorders. While the number of patients requiring a liver
transplant increases, the number of livers donated following cardiac
death (DCD) or brain death (DBD) donated in Europe has not increased
at the same pace. Furthermore, the number of livers coming from
healthy young people, deceased in fatal car accidents has decreased.
Organ shortage has been compensated in Asian countries with increas-
ing numbers of living-donor liver transplantation (LDLT). In western
countries the limitation has fostered the need to extend donor's criteria,
in particular the degree of steatosis considered acceptable has been
increased [11].
Steatosis is an important risk factor in liver surgery due to the
special sensitivity of the steatotic liver to ischemia reperfusion injury
(IRI), [12], which impairs liver regeneration and is a major cause of
liver damage [13]. The exact mechanism responsible for the increased
susceptibility is not fully understood, but clearly involves mitochondrial
dysfunction. The steatotic liver produces higher levels of mitochondrial
ROS [14], both baseline and in response to ischemia reperfusion (IR),
reduced levels of antioxidants [15] and has a reduced capacity to
recover normal ATP levels following reperfusion, leading to enhanced
cell death [16]. A recent study further showed that the steatotic liver
has reduced electron transport chain (ETC) complex I (CI) activity both
baseline and in response to IR, and more importantly, CI activity did not
recover even following long reperfusion times [13]. The CI complex is a
major site of generation of superoxide in the mitochondria [17].
Despite improved allograft preservation techniques many livers
continue to go unused and many studies have attempted to develop
protocols that improve the safety of steatotic liver transplants with
limited success. A particular focus of attention has been the ischemic
preconditioning protocol (IPC) ﬁrst described in the heart [18]. The
liver is conditioned with a brief ischemic period followed by reperfu-
sion, prior to sustained ischemia. IPC boost the resistance of the liver to
a longer ischemic insult. It has been used and tested in many
experimental and some clinical contexts but so far it has not shown
general clinical beneﬁt and its use is not clinically implemented [19].
The molecular pathways involved in IPC have been extensively
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characterized. IPC suppresses neutrophil inﬁltration, decreases the
production of oxygen free radicals and increases antioxidant activity
in the hepatocyte, prevents the activation of the apoptotic cascade and
the occlusion of microvessels [20]. Importantly, it has been suggested
that all these eﬀects are mediated through the protection of mitochon-
drial function [21].
2. Ischemic-preconditioning
Among the many possible strategies to rescue steatotic livers before
transplantation in clinical and experimental studies [22], important
eﬀorts have focused on the applicability of IPC protocols to the steatotic
liver that would allow their use in transplants [23]. However, despite
some limited improvement in some liver damage biomarkers (ie ATL),
the lack of signiﬁcant positive eﬀect in clinical outcome have so far
prevented its translation to the clinical setting, possibly related to the
failure to recover the mitochondrial CI activity noted for the steatotic
liver following IR [13] and the associated loss in ROS homeostasis.
Evidence for oxidative stress might seem an almost irrelevant or
non-speciﬁc ﬁnding, since there is a plethora of pathological conditions
associated with oxidative stress, in fact all that involve inﬂammation,
that the correlation may seem of little clinical relevance. However,
accumulated data indicate otherwise. Increased ROS levels following
the reperfusion phase have been shown to be the main triggering factor
responsible for the induction of hepatocyte cell death following IR, and
are therefore, the key mediators of acute liver failure following liver
transplant [24,25]. Furthermore, sustained low-grade oxidative stress
has been proposed to promote pathological progression to liver ﬁbrosis
and could be associated to an increased risk of mid-term graft failure
[26].
During the ischemic phase, ATP depletion is compensated through
the increase in the anaerobic catabolism of glucose, producing an
increase in lactate levels and a drop in the intracellular pH. This drop
activates the Na+/H+ anti-porter, and the ensuing increase in intra-
cellular Na+ levels cannot be compensated due to the limiting ATP
concentrations, leading to an increase in the intracellular levels of
Ca2+, and facilitates the activation of pro-apoptotic pathways. Once
perfusion is restored the sudden increase in O2 levels produces a
mitochondrial burst of ROS, that together with the elevated Ca2+ and
the low pH can induce the opening of the MTP and result in cell
apoptosis [27].
Following reperfusion, ROS induce inﬂammation in two phases, an
initial or acute phase, and a late or sub-acute phase [28]. The acute
phase corresponds to the ﬁrst 6 h following reperfusion, in this stage
mitochondrial ROS seem essential for the activation of the Kuppfer
cells, that will later mediate the release of proinﬂammatory cytokines
[29].
The sub-acute phase is the inﬂammatory stage, characterized by a
massive inﬁltration of neutrophils, release of cytotoxic and proinﬂam-
matory mediators, and activation of the mesenchymal stem cells, that
can contribute to the development oﬃbrosis. During this stage, the
main source of ROS are the NOX enzymes and work as ampliﬁers of the
inﬂammatory reaction [26].
At the molecular level, elevated ROS levels boost the inﬂammatory
cascade, at least partially through the direct activation of the transcrip-
tion factor NF-κB [30], although there are other indirect mechanisms
through which ROS can also promote a pro-inﬂammatory status
increasing the levels/activity of TGF-β, TNFα and IL-1ß among others
[31].
3. ROS, preconditionong mediators
However, ROS do not only have deleterious eﬀects, ROS dependent
signaling is a crucial mediator of ischemic preconditioning. Therefore,
increased ROS production following IR is a necessary step during liver
preconditioning [32]. ROS trigger many cellular responses that could
potentially contribute to ischemic preconditioning. In particular, ROS
facilitates the activation of AMPK and stabilization of the transcription
factor HIF-1α, resulting in a shift in the cellular metabolism, that makes
the liver more glycolytic and less dependent on O2. This compensatory
eﬀect facilitates survival immediately following reperfusion, since
during reperfusion not all the tissue recovers immediately a normal
oxygen tension and capillaries tend to collapse [33]. Recovery of
normal tissue perfusion depends on the formation of new microvessels,
a process that can take about two weeks to be successfully completed
and that largely depends on the HIF-1α dependent activation of the
angiogenesis mediator VEGF-A [34,35].
The picture that emerges is that ROS play a double edged role in IR,
on one hand promotes apoptotic cell death and induces inﬂammatory
mediators, on the other hand, facilitates cell survival in hypoxic
conditions and induces antioxidant defenses.
ROS dependent IRI is to a large extent dependent on the tissue levels
of antioxidants. In fact, reduced levels of the antioxidant proteins
MnSOD, catalase and GPx have been associated with larger lesions
while forced increase of antioxidants has the opposite eﬀect [36,37].
Conversely, ROS exposure can result in the induction/activation of
antioxidant systems through the activation of the transcription factors
nuclear factor erythroid 2-related factor 2 (Nrf2) [38,39] and the
transcriptional coactivator PGC-1α have been shown to be activated/
induced in response to oxidative stress and drive the increased
expression of antioxidant systems in hepatocytes [40–42].
Nrf2 is considered a master regulator of cellular redox homeostasis
[39]. Under normal conditions Keap1 binds to Nrf2 in the cytoplasm,
and promotes its degradation by the proteasome. Exposure to ROS leads
to Keap1, Nrf2 stabilization and nuclear translocation where it binds to
the anti-oxidant response element (ARE) to induce the expression a set
of antioxidant genes [43]. Is has been proposed that following IR
induction of Nrf2 plays a key role in the control of the inﬂammatory
response, reducing apoptotic cell death [44].
PGC-1α is a master regulator of mitochondrial biogenesis and
activity [45]. Oxidative catabolism is associated with increased mito-
chondrial production of superoxide. To prevent oxidative stress in
conditions of high mitochondrial oxidative activity PGC-1α also con-
trols the expression of several antioxidant proteins [41]. PGC-1α is
highly expressed in the liver where it controls both oxidative catabo-
lism and gluconeogenesis in response to reduced nutrient availability
[46]. PGC-1α levels are highly sensitive to the nutritional status being
induced by starvation and inhibited by feeding [47]. Importantly, in the
steatotic liver PGC-1α levels are reduced [48] and this downregulation
results in a reduction of antioxidant systems in the liver [49]. This fact,
together with the observation of a protective role of PGC-1α in IR
tolerance in the liver [49] and several other tissues (ie heart, kidney,
the central nervous system (CNS)) [50–52] suggest that PGC-1α
regulation of antioxidant systems can be relevant in the enhanced
sensitivity of the steatotic liver to IR. This concept is supported by the
observation that in terms of liver damage following IR, PGC-1α KO
mice behave similarly to WT mice with steatotic livers [49].
4. ROS homeostasis
In order to elucidate the reason why the steatotic liver, that
produces more ROS than the normal liver, cannot precondition, some
studies have focused on the evaluation of the activity of antioxidant
enzymes and found conﬂicting results, with some enzymes being over-
expressed in the steatotic liver and some others with reduced levels in
steatosis [15]. Importantly, several studies have shown the positive
eﬀects of antioxidants against IR injury [53] suggesting that the
steatotic liver has lost its capacity to modulate the production of ROS
and hence of using ROS as signaling mediators. The study by Sanchez
Ramos et al. [49] showed that while the normal liver responds to IR
inducing PGC-1α and antioxidant gene expression, and this induction is
further enhanced by preconditioning, the steatotic liver shows a
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signiﬁcant reduction in its capacity to induce antioxidant gene expres-
sion in response to IR and IPC protocols. Furthermore, the study
supports the notion that this induction depends on PGC-1α, since
PGC-1α KO mice also fail to induce PGC-1α and antioxidant gene
expression in response to IR.
The work by C. Sanchez et al. has demonstrated that the down-
regulation of the transcriptional co-activator PGC-1α in the steatotic
liver limits its capacity to control antioxidant enzyme levels and to
modulate them in response to IR. In the healthy liver, in response to IR,
PGC-1α levels are induced and this induction results in the augmenta-
tion of the cellular antioxidant defenses. In steatosis, not only PGC-1α
levels are reduced but the steatotic liver fails to induce PGC-1α and its
target antioxidant genes in response to IR, resulting in enhanced liver
damage. Aiming to understand why PGC-1α levels are regulated in
response to IR, the same study analyzed why the steatotic liver fail to
induce them in response to IR.
5. ROS control following hypoxia
It is not at all clear how ROS work in preconditioning to protect the
mitochondria from depolarization following IR and how do they work
to attenuate the inﬂammatory response. Recent identiﬁcation of
NDUFA4L2 (NADH dehydrogenase [ubiquinone] 1 alpha subcomplex,
4-like 2) as an hypoxia sensitive inhibitor of complex I has served to
demonstrate the relevance of a pathway that controls mitochondrial
ROS production in response to ischemia [54]. Taking into account that
NDUFA4L2 is a HIF-1α induced protein, HIF-1α stabilization is ROS
sensitive [55] and HIF-1α is induced following IR in the liver [56], it is
tempting to speculate that its induction must also be ROS sensitive,
what would provide a mechanism that could explain ROS dependent
mitochondrial protection. An important open question is what happens
in the fatty liver, where ROS are produced but do not seem to exert their
protective eﬀects while they do exert their damaging eﬀects. Activation
of HIF-1α does not seem to be impaired in the steatotic liver, in fact
HIF-1α activity is higher in the fatty liver than in the normal liver
[57,58].
PGC-1α levels are also regulated by oxygen tension [59]. This
regulation could seem a paradoxical eﬀect, since oxidative metabolism
requires oxygen and limiting oxygen availability may result in mito-
chondrial dysfunction. The physiological relevance of this regulation
seems related to the PGC-1α dependent induction of VEGF-A levels that
promote angiogenesis to increase tissue perfusion and allow oxidative
metabolism [60]. However, C. Sanchez and col. [49] showed that
severe hypoxic conditions actually down-regulate PGC-1α levels at least
in cell culture conditions while restoration of normal oxygen tension
results in the induction of PGC-1α levels, indicating that induction of
PGC-1α following IR in vivo, is likely to occur during the reperfusion
phase.
Taking into account that reperfusion is associated with a burst in
mitochondrial ROS, and that is has been previously demonstrated that
ROS induce PGC-1α expression, is likely that ROS are key mediators in
PGC-1α induction following IR, and the lack of an adaptive response in
the steatotic liver also relate to the inability in this context of ROS to
induce PGC-1α (Fig. 1).
The association of liver steatosis with oxidative stress results in a
low-grade chronic inﬂammatory proﬁle, that is generally associated
with poor inﬂammatory resolution proﬁles, with a limited M2 macro-
phage activation [61,62]. In contrast, acute exposure to ROS promotes
concomitant activation of M1 and M2 macrophages and expression of
resolution cytokines [63,64]. Although the mechanisms are only
partially elucidated, these eﬀects could be also relevant in ROS
dependent preconditioning eﬀects and its failure in the steatotic liver.
Importantly, M2 activation has been shown to be strongly dependent on
the activation of oxidative phosphorylation and mitochondrial function
[65], feasibly via PGC-1α.
6. Translation into the clinical setting
The challenge now is to translate this knowledge into clinical
applications. There are some clinical studies in human patients focused
in the role of oxidative stress in IRI and postoperative complications in
patients after an orthotopic liver transplant (OLT). Since we are not
able to measure the levels of ROS in humans due to their short lifetime,
others strategies are followed in these clinical studies, as measure
oxidative markers, such as lipid peroxidation; the levels of glutathione
or enzymatic antioxidants, such as superoxide dismutase (SOD),
catalase or peroxiredoxins in blood samples or liver biopsies [66].
Recent clinical researches show that also in humans during ischemia
the amounts of ROS increase resulting in oxidative stress imbalance as
evidenced by an increase in oxidative stress markers and antioxidant
response [67–69] and this oxidative imbalance persist in late post-
operative stage (1 year after liver transplant) [70]. Additionally, as
noted above, steatotic livers have poor prognosis in liver transplant that
is associated to evidence of mitochondrial dysfunction and enhanced
production of ROS [71].
The gene expression proﬁle of transplanted liver versus normal liver
shows an induction of stress response genes in transplanted livers, as
well as an increase of liver metabolism and inﬂammatory response.
When transplanted livers subjects were analyzed for the correlation of
transaminase levels, as hepatic injury marker and the expression of
oxidative stress genes, it was found that oxidative stress response
signiﬁcantly correlated with liver injury [72] most probably due to the
generation of higher amounts of ROS in these livers. Related to this
study, it has also been described that the levels of lipid peroxidation
increase at 1 h post-operation and are maintained over basal levels up
to 5 days following liver transplant. Lipid peroxidation in turn
correlates with the upregulation of enzymatic antioxidants such as
superoxide dismutase (SOD), catalase, glutathione peroxidase (GPx)
and glutathione reductase (GR) [69]. Furthermore, the level of lipid
peroxidation also correlates with pre-operative hepatic injury markers
such as bilirubin, AST, ALT, model of end-stage liver disease score
(MELD score), International Normalized Ratio (INR) and with expres-
sion of pro-inﬂammatory cytokines [73].
From this perspective, several strategies have been devised to
decrease hepatic transplant failure due to oxidative stress trying to
avoid the generation of ROS during ischemia and reperfusion. These
strategies include ischemic preconditioning (IPC), antioxidant therapy
and graft preservation in external perfusion machines. Even though the
protective eﬀect of IPC in IRI has been amply demonstrated in pre-
clinical studies, clinical studies have shown conﬂicting results in
normal and steatotic livers [23,74]. Some studies support the protective
eﬀect of IPC in human liver ischemia [75–77] even in steatotic livers,
while other studies indicate that IPC do not have clinical relevance in
liver transplantation [78,79] suggesting that new approaches are
needed to facilitate the use of IPC protocols in the clinical setting.
Early evidence on the role of ROS in IR injury led to the evaluation
of antioxidant administration as a possible therapeutical approach.
Glutathione is the major antioxidant system and some precursors of
glutathione have been evaluated as IRI treatment, such as N-
Acetylcysteine (NAC) or L-Alanyl-Glutamine with conﬂicting results.
NAC was described as a possible antioxidant treatment against IRI [80]
but failed when is administrated during graft cold preservation [81,82],
moreover, other studies do not support the protective role of NAC in IRI
[83]. In a meta analysis of several clinical studies on NAC treatment the
authors concluded that NAC administration improved transaminase
levels but without patient or graft survival correlation [84]. L-Alanyl-
Glutamine has promising results decreasing lipid peroxidation after
liver transplantation [85] but more clinical results are required.
Another antioxidant tested for IRI is melatonin, an antioxidant pro-
duced in the pineal gland that showed a protective eﬀect against IRI,
supraphysiological doses of melatonin improve the general outcome
after liver resection [86,87]. Finally, there is a study on Propofol, an
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anesthetic compound with antioxidant features, in IRI of liver trans-
plant recipients. The authors showed an improvement on lipids
peroxidation in the recipients anesthetized with Propofol [88]. Prob-
ably, antioxidant therapy could improve their eﬃcacy with a synergis-
tic approach, using antioxidants both in recipients and grafts without
forgetting the important role of ROS in cell signaling.
Graft preservation during ischemia is a critical step in liver
transplant, since high amounts of ROS are produced at this stage
[89]. Storage solutions are a good way to treat ROS production during
graft ischemia. A review of diﬀerent preservation solutions correlates
poor prognosis with those livers preserved in solutions with less
antioxidants [90]. In other studies, the authors attribute the protection
eﬀect of Institut Georges Lopez preservation solution (IGL-1) on their
antioxidant eﬀect, decreasing ROS levels and mitochondrial damage
[91]. In addition, storage solution supplemented with a recombinant
Manganese Superoxide Dismutase (rMnSOD) showed eﬃciency redu-
cing O−2 levels in human liver biopsies from donors of hepatic
transplantation [92].
In the last decade a novel technology, a hypothermic preservation
machine, was developed and implemented to avoid the deleterious
eﬀects of ischemia in organs transplantation. First studied in kidney
grafts, some liver studies with hypothermic machine preservation
(HMP) were realized. HMP showed an improvement of graft function
after transplantation, with less hepatic injury markers [93] and later
were described the increase of several antioxidants markers, as
upregulation of SOD or HIFα [94]. Regarding the temperature storage
in the preservation machine, an improvement of mitochondrial function
of excluded livers for transplantation was described [95].
7. Conclusions
In sum, oxidative stress has a harmful eﬀect in hepatic IRI in
humans as seen in animal models. Limiting ROS production with
diﬀerent approaches or with a synergistic approach may improve the
graft function and recipient survival. However, antioxidant treatments
aiming at reducing liver injury have not reached the clinical stage. This
failure could be related to the fact that ROS are signaling mediators,
whose absence can be as detrimental as their excess. In fact, antioxidant
treatment prevents ischemic preconditioning, which can also result
from the “dual” nature of many antioxidants. They are in fact molecules
that can also work as pro-oxidants depending on the redox status of the
environment, being strongly modulated by the levels of reducing
equivalents, oxygen, pH and they can also propagate pro-oxidant
eﬀects. The obvious alternative, the induction of PGC-1α levels also
has strong caveats, as demonstrated by studies where over-expression of
PGC-1α resulted in the loss of metabolic plasticity. For example, the
tolerance of a tissue to hypoxia depends on its ability to sustain a
glycolytic non-oxidative metabolism, and forced mitochondrial activity
would result in mitochondrial induced cell death.
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